[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657168":3},{"organization":4,"outcomesModule":7,"designInfo":64,"detailedDescription":67,"studyPopulation":68,"armGroups":69,"interventions":75,"overallOfficials":63,"centralContacts":80,"locations":63,"responsibleParty":90,"collaborators":63,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":63,"enrollmentInfo":101,"targetDuration":104,"studyType":105,"phases":63,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":123,"whyStopped":63,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":63},{"fullName":5,"class":6},"Deutsche Gesellschaft für Lipidologie e. V. (DGFL) - Lipid-Liga","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":63},[9],{"measure":10,"description":11,"timeFrame":12},"LDL-C target attainment","The primary endpoint of the study\u002Fregistry is the achievement and maintenance of the LDL-C target level recommended by the current ESC\u002FEAS guidelines for high-risk cardiovascular patients during the follow-up period. Assessment is based on documented LDL-C measurements taken at specified time points (after 6 weeks, 3, 6, and 12 months, as well as during the subsequent long-term follow-up).","12 months",[14,18,22,26,29,32,35,39,42,45,48,51,54,57,60],{"measure":15,"description":16,"timeFrame":17},"Absolute change in LDL cholesterol","Absolute change in LDL cholesterol concentration from the baseline or discharge value to the predefined follow-up assessments.\n\nUnit: mg\u002FdL","Baseline to 60 month",{"measure":19,"description":20,"timeFrame":21},"Percentage change in LDL cholesterol","Percentage change in LDL cholesterol concentration from the baseline or discharge value to the predefined follow-up assessments.\n\nUnit: %","Baseline to 60 Month",{"measure":23,"description":24,"timeFrame":25},"Body weight","Body weight documented for registry participants. Unit: kg","Baseline",{"measure":27,"description":28,"timeFrame":25},"Body height","Body height documented for registry participants. Unit: cm",{"measure":30,"description":31,"timeFrame":25},"Body mass index","Body mass index calculated from documented body weight and height. Unit: kg\u002Fm²",{"measure":33,"description":34,"timeFrame":17},"HDL cholesterol concentration","High-density lipoprotein cholesterol (HDL) cholesterol concentration documented during registry follow-up.\n\nUnit: mg\u002FdL",{"measure":36,"description":37,"timeFrame":38},"Triglyceride concentration","Triglyceride concentration documented during registry follow-up.","Baseline to 60 mionth",{"measure":40,"description":41,"timeFrame":25},"Lipoprotein(a) concentration","Lipoprotein(a) concentration documented during registry follow-up. Unit: nmol\u002FL or mg\u002FdL",{"measure":43,"description":44,"timeFrame":17},"HbA1c","Glycated hemoglobin (HbA1c) value documented during registry follow-up. Unit: %",{"measure":46,"description":47,"timeFrame":17},"hsCRP","High-sensitivity C-reactive protein (hsCRP) concentration documented during registry follow-up.\n\nUnit: mg\u002FL",{"measure":49,"description":50,"timeFrame":25},"Blood pressure","Systolic and diastolic blood pressure documented during registry follow-up. Unit: mmHg",{"measure":52,"description":53,"timeFrame":17},"Changes in lipid-lowering therapy during follow-up","Proportion of participants with a documented change in lipid-lowering therapy during follow-up, including initiation, discontinuation, substitution, or modification of lipid-lowering medication.",{"measure":55,"description":56,"timeFrame":17},"Proportion of participants with documented intensification of lipid-lowering therapy","Proportion of participants with documented intensification of lipid-lowering therapy during follow-up.",{"measure":58,"description":59,"timeFrame":17},"Participant-reported adherence to prescribed lipid-lowering therapy","Participant-reported adherence to prescribed lipid-lowering therapy during registry follow-up.",{"measure":61,"description":62,"timeFrame":17},"Occurrence of cardiovascular events during follow-up","Proportion of participants experiencing at least one cardiovascular event during registry follow-up. Cardiovascular events are defined as recurrent ST-elevation myocardial infarction (STEMI), recurrent non-ST-elevation myocardial infarction (NSTEMI), ischemic stroke, or unplanned coronary revascularization.",null,{"allocation":63,"interventionModel":63,"interventionModelDescription":63,"primaryPurpose":63,"observationalModel":65,"timePerspective":66,"maskingInfo":63},"COHORT","PROSPECTIVE","Germany on Target Registry is a prospective patient registry investigating lipid management and cardiovascular secondary prevention following acute myocardial infarction in Germany.\n\nAdults following ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) may be informed about the registry by participating physicians and medical institutions. The role of the physicians is primarily limited to identifying potentially eligible patients, providing information about the registry and supplying an individual access link or QR code.\n\nFollowing registration and electronic informed consent, further study participation is conducted through the Brite™ digital platform provided by XO Life. Participants provide follow-up information directly through the platform. Relevant laboratory values can be entered manually or obtained from medical documents uploaded by the participant.\n\nBaseline information includes characteristics of the index myocardial infarction, LDL-C values at admission and\u002For discharge, lipid-lowering treatment and relevant cardiovascular risk factors and laboratory parameters. Follow-up assessments document LDL-C values, changes in lipid-lowering therapy and additional clinical information.\n\nThe primary focus of the registry is the proportion of participants achieving the predefined LDL-C target of \\\u003C55 mg\u002FdL and the maintenance of LDL-C target attainment during follow-up.\n\nSecondary objectives include characterization of the longitudinal LDL-C course, changes and escalation of lipid-lowering therapy, treatment adherence, reported suspected adverse drug reactions and cardiovascular events during follow-up.\n\nThe registry does not prescribe a specific lipid-lowering treatment or modification of treatment. Decisions regarding pharmacological treatment remain the responsibility of the participant's treating physicians and are made according to routine clinical care.","Adults aged 18 years or older following an acute ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) treated in Germany. Potential participants are identified and informed about the registry by physicians or medical institutions and voluntarily enroll using an individual access link or QR code.",[70],{"label":71,"type":63,"description":72,"interventionNames":73},"Patients following acute myocardial infarction","Adults following an acute ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) who voluntarily enroll in the Deutschland auf Ziel registry and are prospectively followed through the brite™ platform.",[74],"Other: No study-assigned intervention",[76],{"type":6,"name":77,"description":78,"armGroupLabels":79,"otherNames":63},"No study-assigned intervention","Participants receive medical care according to routine clinical practice. The registry does not prescribe or assign lipid-lowering treatment. Lipid-lowering therapies and subsequent treatment changes are documented as part of the observational data collection.",[71],[81,86],{"name":82,"role":83,"phone":84,"phoneExt":63,"email":85},"Oliver Weingärtner, Prof. Dr. med.","CONTACT","+493641-932-4521","oliver.weingaertner@med.uni-jena.de",{"name":87,"role":83,"phone":88,"phoneExt":63,"email":89},"Lukas Babylon, Dr. rer. nat.","+496051-49084-20","lukas.babylon@lipid-liga.de",{"type":91,"investigatorFullName":63,"investigatorTitle":63,"investigatorAffiliation":63,"oldNameTitle":63,"oldOrganization":63},"SPONSOR","100657168","germany-on-target-registry-100657168",false,"NCT07835282","Germany on Target Registry","DaZiR","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of acute ST-elevation myocardial infarction (STEMI) or non-ST- elevation myocardial infarction (NSTEMI)\n* Provision of informed consent for participation in the registry\n\nExclusion Criteria:\n\n* No informed consent for participation in the registry","ALL","18 Years",{"count":102,"type":103},10000,"ESTIMATED","5 Years","OBSERVATIONAL","Germany on Target Registry (DaZiR) is a prospective, Germany-wide patient registry designed to assess lipid management and low-density lipoprotein cholesterol ( LDL-C) target attainment in adults following acute myocardial infarction (STEMI or NSTEMI).\n\nEligible patients are informed about the registry by treating physicians or their medical teams and receive an individual access link or QR code. Following electronic informed consent and registration, participants provide clinical and follow-up information through the brite™ platform.\n\nClinical data, including LDL-C values and lipid-lowering treatment, can be entered by the participants or obtained from uploaded medical documents. The platform enables participants to follow the course of their LDL-C values and provides reminders for scheduled follow-up data collection.\n\nMedical treatment is determined independently by the treating physicians as part of routine clinical care and is not assigned by the registry. The registry aims to assess LDL-C target attainment over time, changes in lipid-lowering treatment, treatment adherence and cardiovascular outcomes following myocardial infarction.",[108,109],"Myocardial Infarction (MI)","Dyslipidemias",[111,112,113,114,115,116,117,118,119,120,121,122],"LDL Cholesterol","LDL-C","ST-Elevation Myocardial Infarction","STEMI","Non-ST-Elevation Myocardial Infarction","NSTEMI","Lipid-Lowering Therapy","Secondary Prevention","Cardiovascular Disease","Dyslipidemia","Patient Registry","Digital Health","NOT_YET_RECRUITING","2026-09-23",{"date":126,"type":127},"2026-09-28","ACTUAL",{"date":129,"type":103},"2026-12-01",{"date":131,"type":103},"2050-12-31",{"name":5,"class":6}]